Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): A stratified, biopsy-driven, multi-centre, randomised, open label, controlled clinical trial - 16 week outcomes

<p><strong>Background:</strong><br /> Although targeted biological treatments have transformed the outlook for patients with rheumatoid arthritis, 40% of patients show poor clinical response, which is mechanistically still unexplained. Because more than 50% of patients with r...

Full description

Bibliographic Details
Main Authors:	Humby, F, Durez, P, Buch, MH, Lewis, M, Rizvi, H, Rivellese, F, Nerviani, A, Giorli, G, Mahto, A, Montecucco, C, Lauwerys, B, Ng, N, Ho, P, Bombardieri, M, Romão, VC, Verschueren, P, Kelly, S, Sainaghi, PP, Gendi, N, Dasgupta, B, Cauli, A, Reynolds, P, Cañete, JD, Moots, R, Taylor, P, Edwards, CJ, Isaacs, J, Sasieni, P, Choy, E, Pitzalis, C
Format:	Journal article
Language:	English
Published:	Elsevier 2021

Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): A stratified, biopsy-driven, multi-centre, randomised, open label, controlled clinical trial - 16 week outcomes

Similar Items